vigabatrin

FDA Drug Profile — vigabatrin, SABRIL, vigabatrin for oral solution, VIGABATRIN, Vigabatrin

vigabatrin is listed in the FDA National Drug Code directory with 14 NDC codes, marketed under brand names including vigabatrin, SABRIL, vigabatrin for oral solution. Available dosage forms: powder, for solution, tablet, film coated, for solution, solution.

Drug Details

Generic Name
vigabatrin
Brand Names
vigabatrin, SABRIL, vigabatrin for oral solution, VIGABATRIN, Vigabatrin, VIGAFYDE, VIGADRONE
Application Number
ANDA214671
Sponsor
Zydus Pharmaceuticals (USA) Inc.
NDC Codes
14
Dosage Forms
POWDER, FOR SOLUTION, TABLET, FILM COATED, FOR SOLUTION, SOLUTION
Routes
ORAL
Active Ingredients
VIGABATRIN

Indications and Usage

1 INDICATIONS AND USAGE Vigabatrin for oral solution is indicated for the treatment of: Refractory Complex Partial Seizures as adjunctive therapy in patients 2 years of age and older who have responded inadequately to several alternative treatments; vigabatrin for oral solution is not indicated as a first line agent ( 1.1 ) Infantile Spasms - monotherapy in infants 1 month to 2 years of age for whom the potential benefits outweigh the potential risk of vision loss ( 1.2 ) 1.1 Refractory Complex Partial Seizures (CPS) Vigabatrin for oral solution is indicated as adjunctive therapy for adults and pediatric patients 2 years of age and older with refractory complex partial seizures who have inadequately responded to several alternative treatments and for whom the potential benefits outweigh the risk of vision loss [ see Warnings and Precautions ( 5.1 ) ]. Vigabatrin for oral solution is not indicated as a first line agent for complex partial seizures. 1.2 Infantile Spasms (IS) Vigabatrin for oral solution is indicated as monotherapy for pediatric patients with infantile spasms 1 month to 2 years of age for whom the potential benefits outweigh the potential risk of vision loss [ see Warnings and Precautions ( 5.1 )]. 1.1 Refractory Complex Partial Seizures (CPS) Vigabatrin for oral solution is indicated as adjunctive therapy for adults and pediatric patients 2 years of age and older with refractory complex partial seizures who have inadequately responded to several alternative treatments and for whom the potential benefits outweigh the risk of vision loss [ see Warnings and Precautions ( 5.1 ) ]. Vigabatrin for oral solution is not indicated as a first line agent for complex partial seizures. 1.2 Infantile Spasms (IS) Vigabatrin for oral solution is indicated as monotherapy for pediatric patients with infantile spasms 1 month to 2 years of age for whom the potential benefits outweigh the potential risk of vision loss [ see Warnings and Precautions ( 5.1 )].